A website to provide support for people who have or have had any type of cancer, for their caregivers and for their family members.
Results 1 to 2 of 2

Thread: Immunotherapy checkpoint combination trials growing rapidly

  1. #1

    Immunotherapy checkpoint combination trials growing rapidly

    Over the last few months it hasnít been unusual to see new combination studies being announced on a daily basis, matching one of the 5 approved PD-(L)1 checkpoint drugs with another cancer therapy. Some mornings they come in pairs.

    Itís not hard to see why. The checkpoints typically work as a monotherapy ó though there have been some nasty setbacks over the past 6 months. And some of the big players are happy to contribute their drug to studies sponsored by others looking to advance a pilot Phase I/II exploratory study. There are also recent examples of some big tie-ups between Merck (Keytruda) and Bristol-Myers Squibb (Opdivo) checkpoints with Incyte in Phase III.

    Incyte has its own PD-1 in the clinic as it lines up these agnostic late-stage trials to position its leading IDO1 drug.

    Now EP Vantage has tallied the whole score on these combo trials, not coincidentally just ahead of ASCO, and found a stunning 765 combination studies listed on clinicaltrials.gov. Keytruda leads the pack, with 268 ó up from 70 just 18 months ago. For Bristol-Myers itís 242, more than three times the number EP Vantageís editorial team found in 2015.

    Anyone even moderately interested in this field will want to check it out directly. Thereís a lot of detail on whatís now in the clinic.

    Donít expect the rising trend lines to start to plateau anytime soon, either, as Pfizer/Merck KGaA (Bavencio) and AstraZeneca (Imfinzi) start to gain traction on the combo front. Roche already emerged as the number three player in the field with Tecentriq, though its recent Phase III failure for its checkpoint may chill other would-be partners.

    Meanwhile, new checkpoint players like BeiGene and Lilly are moving along, the report notes, while Novartis has been advancing its own in-house checkpoint programs. The second wave of PD-(L)1 therapies will be large.

    One of the key next steps in this field is in AstraZenecaís hands. It has a combo of Imfinzi with an in-house CTLA-4 checkpoint dubbed tremelimumab in the MYSTIC study that will read out soon for lung cancer. Analysts are waiting eagerly to see if it can beat out the competition, or get sidelined by some well-known toxicity concerns.

    One thing is absolutely certain. Bristol-Myers Squibb started as the dominant player in PD-(L)1, then got checked by a surging Merck when it made the wrong clinical move on non-small cell lung cancer. AstraZeneca, the last of the big 5 to land an approval, just days ago stunned virtually everyone with positive Phase III data for Imfinzi in unresectable lung cancer, providing early dominance in a significant niche market.

    Just at a time when checkpoints should start getting more predictable, the field seems to be ripe for fresh surprises of all kinds. And that will continue to attract fresh waves of combination studies tackling all kinds of cancers.

  2. #2
    Moderator Senior User IndyLou's Avatar
    Join Date
    Jan 2014
    Posts
    470
    This is indeed an exciting time in the field of oncology. I hope that these advances offer new hope for cancer patients, including many of the visitors to this site.
    Age 52 Male
    early Feb, 2013 - Noticed almond-sized lump in shaving area, right side of neck. No other "classic" cancer symptoms
    late Feb, 2013 - Visited PCP for check-up, PCP advised as lymphoma. Did blood work, orders for CT-scan, referred to ENT
    3/7/13 - CT-scan inconclusive, endoscopy negative
    3/9/13 - FNA of neck mass
    3/14/13 - Received dx of squamous-cell carcinoma, unknown primary
    3/25/13 - CT-PET scan reveals no other active tumors
    3/26/13 - work/up for IMRT
    4/1/13 - W1, D1 of weekly cetuximab
    4/8/13 - W1, D1 of IMRT
    5/20/13 - complete 8 week regimen of weekly cetuximab
    5/24/13 - Complete 35-day regimen of daily IMRT
    mid-July 2013 - CT-PET scan reveals no active tumors, but shows necrotic tissue at site of original tumor
    early Sept 2013 - partial neck dissection to remove necrotic tissue. Assay shows no cancer present.
    Spring 2014 - No signs of cancer
    Spring 2015 - NED
    Spring 2016 - NED
    Spring 2017 - NED
    Spring 2018 - NED
    Spring 2019 - NED

 

Similar Threads

  1. Indolent lymhomas: Vaccination/checkpoint inhibitors/low-dose rads promising.
    By po18guy in forum Lymphoma - Hodgkin's and Non-Hodgkin's Lymphoma Forum
    Replies: 2
    Last Post: 12-14-2016, 10:08 PM
  2. Immunotherapy trials for Colorectal Cancer?
    By getting there in forum Colon Cancer and Rectal Cancer Forum
    Replies: 1
    Last Post: 06-04-2015, 08:37 AM
  3. Checkpoint Inhibitors herald advances against lymphoma
    By po18guy in forum Lymphoma - Hodgkin's and Non-Hodgkin's Lymphoma Forum
    Replies: 0
    Last Post: 01-14-2015, 08:13 PM
  4. How rapid is a rapidly growing lymph node?
    By lumpy in forum Lymphoma - Hodgkin's and Non-Hodgkin's Lymphoma Forum
    Replies: 1
    Last Post: 08-24-2012, 06:15 AM
  5. Mel Metastatic Tumors Shrink Rapidly in Euro-PLX4032 Trial
    By HaoleBoy in forum Melanoma and Skin Cancer Forum
    Replies: 0
    Last Post: 10-28-2009, 12:46 AM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •